BUSINESS
Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
Japan’s pharma industry is resuming its operations after the lifting of the country’s state of emergency declaration. The Japan arm of Sanofi has introduced a rule under which its reps continue to work from home…

LATEST

May 29, 2020
Otsuka Holdings’ pharmaceutical revenue in the first quarter of 2020 grew over 13%, driven by four global brands including the selective vasopressin V2 receptor antagonist tolvaptan and the antipsychotic Abilify Maintena (aripiprazole), according to its earnings released on May 28.In…
May 29, 2020
A key health ministry advisory panel on May 28 cleared Novartis’ asthma drug known as Enerzair, which will be the first triple combination inhaled therapy for the disease, along with a batch of other medicines. If all goes well, they…
May 29, 2020
The Federation of Japan Pharmaceutical Wholesalers Associations (JPWA) on May 28 adopted a resolution leaning on the government to revisit its plan to conduct so-called “off-year” drug re-pricing, beginning in April 2021, in view of the current COVID-19 crisis.In the…
By Kazuhiro Chiboshi

The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…

By Takamitsu Sasai

When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…

By Takamitsu Sasai

Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

By Takashi Ebisawa

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA